ATE353223T1 - Multi-komponenten impfstoff zum schutz vor krankheiten die durch haemophilus influenza und moxarella catarrhalis ausgelöst werden - Google Patents

Multi-komponenten impfstoff zum schutz vor krankheiten die durch haemophilus influenza und moxarella catarrhalis ausgelöst werden

Info

Publication number
ATE353223T1
ATE353223T1 AT00945494T AT00945494T ATE353223T1 AT E353223 T1 ATE353223 T1 AT E353223T1 AT 00945494 T AT00945494 T AT 00945494T AT 00945494 T AT00945494 T AT 00945494T AT E353223 T1 ATE353223 T1 AT E353223T1
Authority
AT
Austria
Prior art keywords
antigens
antigen
component
moraxella catarrhalis
haemophilus influenzae
Prior art date
Application number
AT00945494T
Other languages
English (en)
Inventor
Sheena M Loosmore
Yan-Ping Yang
Michel H Klein
Ken Sasaki
Original Assignee
Sanofi Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23389874&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE353223(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Pasteur Ltd filed Critical Sanofi Pasteur Ltd
Application granted granted Critical
Publication of ATE353223T1 publication Critical patent/ATE353223T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AT00945494T 1999-07-15 2000-07-11 Multi-komponenten impfstoff zum schutz vor krankheiten die durch haemophilus influenza und moxarella catarrhalis ausgelöst werden ATE353223T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/353,617 US6391313B1 (en) 1999-07-15 1999-07-15 Multi-component vaccine to protect against disease caused by Haemophilus influenzae and Moraxella catarrhalis

Publications (1)

Publication Number Publication Date
ATE353223T1 true ATE353223T1 (de) 2007-02-15

Family

ID=23389874

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00945494T ATE353223T1 (de) 1999-07-15 2000-07-11 Multi-komponenten impfstoff zum schutz vor krankheiten die durch haemophilus influenza und moxarella catarrhalis ausgelöst werden

Country Status (12)

Country Link
US (1) US6391313B1 (de)
EP (2) EP1200122B1 (de)
AT (1) ATE353223T1 (de)
AU (1) AU767096B2 (de)
CA (1) CA2378862C (de)
CY (1) CY1107620T1 (de)
DE (1) DE60033291T2 (de)
DK (1) DK1200122T3 (de)
ES (1) ES2280230T3 (de)
PT (1) PT1200122E (de)
SI (1) SI1200122T1 (de)
WO (1) WO2001005424A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440425B1 (en) * 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
NZ517235A (en) * 1999-07-27 2004-01-30 Aventis Pasteur Recombinant high molecular weight major outer membrane protein of moraxella
SE0102410D0 (sv) * 2001-07-04 2001-07-04 Arne Forsgren Novel surface exposed immunoglobulin D-binding protein from moraxella catarrhalis
WO2010008411A1 (en) 2007-11-09 2010-01-21 The Salk Institute For Biological Studies Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
CN105175549B (zh) * 2015-09-30 2019-08-16 康希诺生物股份公司 一种流感嗜血杆菌融合蛋白及其构建方法与应用
US11167022B2 (en) 2017-03-31 2021-11-09 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
WO2018178265A1 (en) * 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496538A (en) 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
CA2047681C (en) * 1989-03-09 2000-02-01 Bruce A. Green Vaccines for nontypable haemophilus influenzae
US5843463A (en) 1990-12-21 1998-12-01 Antexbiologics, Inc. Adhesin-oligosaccharide conjugate vaccine for Haemophilus influenzae
US5603938A (en) 1992-03-16 1997-02-18 St. Louis University High molecular weight surface proteins of non-typeable haemophilus
US5977336A (en) 1993-03-16 1999-11-02 St. Louis University High molecular weight surface proteins of non-typeable haemophilus
BR9406589A (pt) * 1993-03-16 1996-01-30 Univ St Louis Vacina contra doença causada por haemophilus influenzae não tipificável
US5712118A (en) * 1993-09-29 1998-01-27 Research Foundation Of State University Of New York Vaccine for branhamella catarrhalis
US5506139A (en) 1994-07-21 1996-04-09 Connaught Laboratories Limited Analog of haemophilus Hin47 with reduced protease activity
US6764682B1 (en) 1994-06-16 2004-07-20 Aventis Pasteur Limited Adjuvant compositions containing more than one adjuvant
CA2171611C (en) 1994-07-21 2001-05-29 Sheena Loosmore Analog of haemophilus hin47 with reduced protease activity
US5646259A (en) 1995-03-24 1997-07-08 St. Louis University DNA encoding haemophilus adhesion proteins
US6335018B1 (en) 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
EP1047447A1 (de) * 1998-01-13 2000-11-02 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Lipooligosaccharide enthaltender impfstoff zur verhütung von infektionen mit moraxella (branhamella) catarrhalis in säugetieren
US6974581B1 (en) * 1998-12-15 2005-12-13 Aventis Pasteur Limited Multi-component vaccine comprising at least two antigens from haemophilus influenzae to protect against disease

Also Published As

Publication number Publication date
DK1200122T3 (da) 2007-06-04
EP1880734A2 (de) 2008-01-23
US6391313B1 (en) 2002-05-21
CY1107620T1 (el) 2013-03-13
DE60033291T2 (de) 2007-07-05
CA2378862C (en) 2005-05-10
AU5958600A (en) 2001-02-05
CA2378862A1 (en) 2001-01-25
EP1200122B1 (de) 2007-02-07
PT1200122E (pt) 2007-05-31
WO2001005424A2 (en) 2001-01-25
ES2280230T3 (es) 2007-09-16
EP1200122A2 (de) 2002-05-02
EP1880734A3 (de) 2008-06-25
AU767096B2 (en) 2003-10-30
DE60033291D1 (de) 2007-03-22
SI1200122T1 (sl) 2007-08-31
WO2001005424A3 (en) 2001-08-02

Similar Documents

Publication Publication Date Title
EP1398379A3 (de) Zusammensetzungen zur Immuntherapie und Diagnose von Tuberculosis
DE69529219T2 (de) Helicobacter proteine und impstoffe
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
KR890701758A (ko) 재조합 dna에서 유도한 보르데텔라 외독소 소단위체의 유사체 및 그를 포함하는 백신
NO20075902L (no) Forbindelser for immunoterapi og diagnose av turberkolose og metoder for deres anvendelse
ATE442163T2 (de) Lawsonia intracellularis europäischen ursprungs und vakzine, diagnostika und anwendungsverfahren dafür
ATE217196T1 (de) Impfstoff auf urease-basis gegen helicobacter infektionen
NO991694L (no) Forbindelser og metoder for immunoterapi og diagnose av tuberkulose
LU91596I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique,d'antoxine coquelucheuse, d'hémagglutinine filamenteuse, de pertactine, de virus poliomyélitique inactivé type 1, type 2 et type 3 et de polyoside capsulaire d'haemophilus influenzae type b (Infanrix - IPV/Hib)
WO2003065973A8 (en) Multivalent streptococcal vaccine compositions and methods for use
WO1998046725A3 (en) Attenuated, invasive vaccines against fish pathogens
CY1106252T1 (el) Εμβολιο πολλαπλων συστατικων που πepιλαμβανει τουλαχιστον δυο αντιγονα απο haemophilus influenzae για την προστασια εναντι νοσησης
CY1107620T1 (el) Πολυ-συστατικο εμβολιο για την προστασια εναντι της παθησης που προκαλειται απο haemophilus influenzae and moraxella catarrhalis
FI924457A (fi) Kompositioner och behandlingsfoerfarande foer lunginflammation i djur
DE68915046D1 (de) Haemophilus influenzae Typ B Polysaccharid-Aussermembranprotein-Konjugat als Impfstoff.
HUP9904171A2 (hu) A ragadós száj- és körömfájás vírusok immunogén peptidjei
WO2000051633A3 (en) MULTI-COMPONENT VACCINE COMPRISING AT LEAST THREE ANTIGENS TO PROTECT AGAINST DISEASE CAUSED BY $i(HAEMOPHILUS INFLUENZAE)
WO2002009749A3 (en) Respiratory syncytial virus vaccine
ATE258445T1 (de) Impfstoff beinhaltend bacterin und toxoid aus pasteurella haemolytica typ a-1
ATE401341T1 (de) Vakzine enthaltend omp85 proteine von neisseria gonorrhoeae und neisseria meningitidis
WO1997046255A3 (en) Vaccine composition comprising outer membrane protein fragments of bordetella pertussis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1200122

Country of ref document: EP